secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0001297184-26-000013
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar enters supply agreement with related party Letop, amends contract with Hanxin
--------------------------------------------------------------------------------

- Supply agreement with Nanjing Letop (Henry Zhang, son of CEO); no minimum purchase, 5-year term.
- Contract Research Amendment shifts work from AMP-107 to AMP-105; total cost increased by ~$0.6M.
- Both transactions are related-party and approved by Audit Committee; deemed not material.
- Payments under supply agreement will be made in Chinese yuan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718426000013/0001297184-26-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718426000013/amph-20260303x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-26-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer